Display options
Cite
Moes JJ, Stuurman FE, Hendrikx JJ, et al. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug Deliv Transl Res. 2013;3(3):243-51doi: 10.1007/s13346-012-0127-6.
Moes, J. J., Stuurman, F. E., Hendrikx, J. J., Marchetti, S., Huitema, A. D., Beijnen, J. H., Schellens, J. H., & Nuijen, B. (2013). Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug delivery and translational research, 3(3), 243-51. https://doi.org/10.1007/s13346-012-0127-6
Moes, Johannes J, et al. "Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet." Drug delivery and translational research vol. 3,3 (2013): 243-51. doi: https://doi.org/10.1007/s13346-012-0127-6
Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug Deliv Transl Res. 2013 Jun;3(3):243-51. doi: 10.1007/s13346-012-0127-6. PMID: 25788133.
Copy Download .nbib Format: NLM
Share it on

Drug Deliv Transl Res. 2013 Jun;3(3):243-51. doi: 10.1007/s13346-012-0127-6.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

Drug delivery and translational research

Johannes J Moes, Frederik E Stuurman, Jeroen J M A Hendrikx, Serena Marchetti, Alwin D R Huitema, Jos H Beijnen, Jan H M Schellens, Bastiaan Nuijen

Affiliations

  1. Department of Pharmacy & Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands, [email protected].

PMID: 25788133 DOI: 10.1007/s13346-012-0127-6

Abstract

The ability to deliver the potent anti-cancer agent docetaxel via the oral route may enable the development of promising new treatment regimens with reduced toxicity, increased efficacy, and increased patient convenience. Recently, we were able to overcome the low oral bioavailability of docetaxel by concomitant administration of the pharmacokinetic booster ritonavir and the design of an oral solid dispersion formulation of docetaxel (ModraDoc001 10-mg capsule). Further research lead to the development of a docetaxel tablet (ModraDoc003 10-mg tablet) and a fixed-dose combination (FDC) tablet of docetaxel and ritonavir (ModraDoc004 10/50-mg tablet). In this clinical proof-of-concept study the exposure to docetaxel and ritonavir was compared between the single agent formulations and the FDC tablet. Six evaluable patients received 40 mg docetaxel and 200 mg of ritonavir once a week according to a cross-over design. No significant differences were found in the exposure to docetaxel and ritonavir between the single agent formulations and the FDC tablet. There was, however, a tendency towards a higher exposure to docetaxel after the administration of the FDC tablet, which could be an effect of the simultaneous release of docetaxel and ritonavir in the gastrointestinal tract. The FDC tablet of docetaxel and ritonavir is a pharmaceutically and clinically feasibly option in the development of patient convenient oral anti-cancer therapy with docetaxel.

References

  1. Drug Metab Dispos. 2008 Feb;36(2):205-16 - PubMed
  2. J Clin Oncol. 1998 Jan;16(1):187-96 - PubMed
  3. Pharm Res. 1995 Mar;12(3):413-20 - PubMed
  4. Eur J Clin Pharmacol. 2007 Jun;63(6):571-81 - PubMed
  5. Am J Med. 2007 Aug;120(8):713-9 - PubMed
  6. Clin Cancer Res. 2009 Jun 15;15(12):4228-33 - PubMed
  7. Int J Pharm. 2011 Nov 28;420(2):244-50 - PubMed
  8. Br J Cancer. 2005 Jul 25;93(2):173-7 - PubMed
  9. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):137-49 - PubMed
  10. J Pharm Biomed Anal. 2006 May 3;41(2):676-81 - PubMed
  11. Drug Dev Ind Pharm. 2008 Oct;34(10):1130-9 - PubMed
  12. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Oct 15;879(28):2984-90 - PubMed
  13. Drug Dev Ind Pharm. 2008 Nov;34(11):1227-37 - PubMed
  14. Cancer Res. 2009 Dec 1;69(23):8996-9002 - PubMed
  15. J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):373-82 - PubMed
  16. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):401-10 - PubMed

Publication Types